Table 3.

Relative risk of co-primary end points by presence of atrial fibrillation/flutter on baseline electrocardiogtram^a

Outcome	Unadjusted	Adjustedb
ACM	0.92 (0.70–1.20), P = 0.537	0.89 (0.66–1.20), P = 0.460
CVM/HHF	1.22 (1.01–1.46), P = 0.035	1.16 (0.95–1.43), P = 0.152

^aData represent hazard ratios and 95% confidence intervals for risk of primary co-endpoints for patients with atrial fibrillation/flutter on baseline ECG relative to patients without atrial fibrillation/flutter on baseline ECG

^bAdjusted for aliskiren treatment, age, gender, ischaemic heart failure aetiology, NYHA functional class, EF, systolic blood pressure, heart rate, NT-proBNP, serum sodium, serum blood urea nitrogen, QRS duration, medical history (prior hospitalization for heart failure, hypertension, CAD, diabetes, COPD), and background therapy (ACE inhibitor/ARB, beta-blocker, mineralocorticoid receptor antagonist, digoxin, implantable cardioverter-defibrillator, CRT). ACM, all-cause mortality; CVM/HHF, cardiovascular mortality or hospitalization for heart failure.